India-headquartered pharma major, Dr Reddy’s Laboratories has launched the authorized generic version of GlaxoSmithKline’s (GSK) ‘Imitrex’ in the US.
The drug, ‘Imitrex’ is used for treating migraine attacks in adults. It will be launched in 25mg, 50mg, and 100mg. Dr. Reddy’s is said to be the first company to launch an authorized generic version of this tablet in the US market. In October 2006, the company announced that it had settled patent litigation with GSK relating to this ‘sumatriptan succinate’ tablets, the generic version of GSK’s ‘Imitrex’.
According to IMS, ‘Imitrex’ tablets had US sales of $1.29 billion in 2007. The specific financial terms and conditions of the settlement have not been disclosed.